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Abstract. 
 
The epidermal growth factor (EGF) family 
of tyrosine kinase receptors (ErbB1, -2, -3, and -4) and 
their ligands are involved in cell differentiation, prolif-
eration, migration, and carcinogenesis. However, it has 
proven difﬁcult to link a given ErbB receptor to a spe-
ciﬁc biological process since most cells express multiple 
ErbB members that heterodimerize, leading to recep-
tor cross-activation. In this study, we utilize carcinoma 
cells depleted of ErbB2, but not other ErbB receptor 
members, to speciﬁcally examine the role of ErbB2 in 
carcinoma cell migration and invasion. Cells stimulated 
with EGF-related peptides show increased invasion of 
the extracellular matrix, whereas cells devoid of func-
tional ErbB2 receptors do not. ErbB2 facilitates cell in-
vasion through extracellular regulated kinase (ERK) 
activation and coupling of the adaptor proteins, 
p130CAS and c-CrkII, which regulate the actin-myosin 
cytoskeleton of migratory cells. Overexpression of 
ErbB2 in cells devoid of other ErbB receptor members 
is sufﬁcient to promote ERK activation and CAS/Crk 
coupling, leading to cell migration. Thus, ErbB2 serves 
as a critical component that couples ErbB receptor ty-
rosine kinases to the migration/invasion machinery of 
carcinoma cells.
Key words: epidermal growth factor • ERK • cell
migration • adaptor proteins • signal transduction
 
Introduction
 
The ErbB family of receptors (ErbB1, -2, -3, and -4)
consists of a cysteine-rich extracellular domain, a single
transmembrane spanning region, and a cytoplasmic tail
containing tyrosine kinase activity and several tyrosine
residues that are phosphorylated upon ligand binding (for
reviews see Hynes and Stern, 1994; Alroy and Yarden,
1997; Riese and Stern, 1998). This family of receptors and
their ligands have been implicated in the genesis of a num-
ber of human carcinomas (Slamon et al., 1989; Dougall
et al., 1994; Hynes and Stern, 1994; Gilbertson et al., 1998).
ErbB2 (HER2/neu) is most notable since amplification of
the ErbB2 gene occurs in a variety of tumors, including
20–30% of breast cancer patients (Hynes and Stern, 1994).
In fact, ErbB2 amplification is used as an independent prog-
nostic indicator of patient survival and is correlated with a
number of adverse prognostic factors in breast cancer, includ-
ing increased occurrence of metastasis and micrometastatic
bone marrow disease (Slamon et al., 1987; Pantel et al., 1993).
The ligands for ErbB receptors can be divided into three
separate groups of peptides that activate distinct sets of in-
dividual receptors (Beerli and Hynes, 1996; Tzahar et al.,
1996; Pinkas-Kramarski et al., 1998; Riese and Stern,
1998). The first group comprises epidermal growth factor
(EGF)
 
1
 
, transforming growth factor alpha (TGF-
 
a
 
), and
amphiregulin, which bind to ErbB1, but not other ErbB
receptor members. The neuregulins (NRG, also known as
neu differentiation factor, NDF, and heregulin), which
specifically bind to ErbB3 and ErbB4, represent the sec-
ond group. The third group consists of 
 
b
 
-cellulin (BTC),
heparin-binding EGF (HB-EGF), and epiregulin, which
bind to ErbB1 and ErbB4. Importantly, ErbB2 is an or-
phan receptor with no characterized ligand, but can be ac-
tivated by homodimerization or in trans by heterodimer-
ization with another ErbB family receptor (Graus-Porta
et al., 1995, 1997; Karunagaran et al., 1996). In fact, ErbB2
has recently been shown to be the preferred heterodimer-
ization partner of all activated ErbB family members
(Graus-Porta et al., 1997). Moreover, there are specific
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heterodimer combinations formed between ErbB2 and
ErbB receptors in response to EGF family peptides (Tza-
har et al., 1996; Pinkas-Kramarski et al., 1998). For exam-
ple, NDF promotes ErbB3 and ErbB4 heterodimerization
with ErbB2, but not with ErbB1. BTC promotes ErbB4 as
well as ErbB1 dimers with ErbB2, but not with ErbB3.
EGF induces primarily ErbB1/ErbB2 heterodimers (Riese
and Stern, 1998).
ErbB2 dimerization with ErbB family members and its
transactivation may allow for the recruitment of distinct
effector molecules leading to diversification of signal
transduction responses. For example, ErbB2, but not
other ErbB members, couple to CHK (Csk-homologous
kinase; Zrihan-Licht et al., 1997). On the other hand, the
protooncogene Cbl forms a complex only with ErbB1
(Levkowitz et al., 1996). The specific interaction of these
effector proteins with ErbB receptors likely result from
differences in tyrosine residues phosphorylated in trans by
distinct ErbB receptor pairs (Olayioye et al., 1998). An im-
portant component of ErbB2-containing heterodimers is
sustained activation of various biochemical signals, includ-
ing the mitogen-activated protein (MAP) kinases, ERK1
and ERK2 (extracellular regulated kinase; Graus-Porta
et al., 1995, 1997; Karunagaran et al., 1996; Pinkas-Kra-
marski et al., 1998). This signaling event may contribute to
the increased metastatic potential associated with ErbB2-
containing tumors, as ERK can regulate both actin-myo-
sin motor activity and proliferation of migratory cells
(Klemke et al., 1997; Nguyen et al., 1999).
Recent evidence indicates that ErbB2 amplification in
cells leads to kinase activation and cell proliferation (Di
Fiore et al., 1987b; Tzahar et al., 1996; Pinkas-Kramarski
et al., 1998; Riese and Stern, 1998). These findings suggest
that aberrant activation of biochemical signals as the result
of ErbB2 overexpression contributes to the development
of metastatic breast cancer. However, the molecular sig-
naling mechanisms responsible for ErbB2-induced malig-
nancy are poorly understood. In fact, it has been difficult
to determine the specific role of ErbB2 signals in a given
biological response as this receptor is widely expressed
and most always in the context of other ErbB members. In
this report, we used cells functionally devoid of ErbB2 to
directly study its role in cell migration and invasion. We
provide evidence that ErbB2 activation by ErbB family re-
ceptors and their ligands is a fundamental event necessary
for carcinoma cell invasion of the extracellular matrix
(ECM). Furthermore, we show that cell invasion induced
by ErbB2 is mediated by ERK activation and the coupling
of the adaptor proteins p130CAS (Crk-associated sub-
strate) and c-CrkII.
 
Materials and Methods
 
Antibodies and Reagents
 
Rabbit antibodies to the ErbB1, -2, -3, -4, p130CAS, and ERK2 were from
Santa Cruz Biotechnology, Inc. Phospho-ERK–specific antibody was
from Promega. Monoclonal antiphosphotyrosine antibody 4G10, rabbit
anti-MEK, and rat tail collagen I were from Upstate Biotechnology, Inc.
Anti-Crk and CAS antibodies were from Transduction Laboratories, Inc.
Functional blocking mAbs to the 
 
b
 
1 integrin subunit (P4C10) and 
 
a
 
v
 
b
 
5
(P1F6) have been described (Leavesley et al., 1992). NDF was from Neo-
Markers. EGF was from Genzyme Corp. 
 
BT
 
C was from Sigma Chemical
Co. Insulin was from Boehringer Mannheim Corp. PD98059 (2-[2
 
9
 
-amino-
3
 
9
 
methoxyphenyl]-oxanaphthalen-4-one) was from Calbiochem-Novabio-
chem Corp.
 
Expression Vectors and Constructs
 
The pEBG expression plasmid containing glutathione S transferase (gst)-
tagged or untagged wild-type CAS, or CAS with an in-frame deletion of
its substrate domain (CAS-SD, aa 213–514) has been described previ-
ously (Mayer et al., 1995). pUCCAGGS vector containing myc-tagged
wild-type or src-homology 2 domain (SH2) mutated c-CrkII (arginine 38
to valine), and vectors encoding full-length human ErbB receptors and
mutationally activated MEK has been described (Matsuda et al., 1993;
Graus-Porta et al., 1995; Klemke et al., 1997). In some cases, ErbB recep-
tor cDNAs were subcloned into pcDNA3 using standard molecular clon-
ing protocols.
 
Haptotaxis Migration Assays
 
The breast adenocarcinoma cell lines MCF7, T47D, and MDA-MB-435,
and derivatives without cell surface ErbB2 receptors have been described
(Graus-Porta et al., 1995; Karunagaran et al., 1996; Pinkas-Kramarski et al.,
1998). Cell adhesion and migration experiments were performed as de-
scribed previously (Klemke et al., 1997, 1998). In brief, migration experi-
ments were performed using modified Boyden chambers (tissue culture
treated, 6.5-mm diam, 10-
 
m
 
m thickness, 8-
 
m
 
m pores, from either Trans-
well, Costar Corp., or the QCM migration kit from Chemicon Interna-
tional, Inc.). The polycarbonate membranes were coated on the underside
of the membrane with 10 
 
m
 
g/ml vitronectin or collagen type I in PBS for
2 h at 37
 
8
 
C, rinsed once with PBS, and were then placed into the lower
chamber containing migration buffer (fibroblast basal medium; FBM with
0.5% BSA; Clonetics). Serum-starved cells were removed from culture
dishes with HBSS containing 5 mM EDTA and 25 mM Hepes, pH 7.2, and
0.01% trypsin, washed twice with migration buffer, and then suspended in
FBM 0.5% BSA (10
 
6
 
 cells/ml). 100,000–200,000 cells were then added to
the top of each migration chamber and allowed to migrate to the under-
side of the top chamber for 2 h in the presence or absence of various con-
centrations of either insulin, EGF, NDF, or 
 
BT
 
C which had been added to
the lower chamber. In some cases, cells were allowed to migrate in the
presence or absence of function blocking antiintegrin antibodies (25 
 
m
 
g/ml).
The nonmigratory cells on the upper membrane surface were removed
with a cotton swab and the migratory cells attached to the bottom surface
of the membrane stained with 0.1% crystal violet in 0.1 M borate, pH 9.0,
and 2% ethanol for 20 min at room temperature. The number of migra-
tory cells per membrane were either counted (with an inverted micro-
scope using a 20
 
3 
 
objective) or the stain eluted with 10% acetic acid and
the absorbance determined at 600 nm, and migration enumerated from a
standard curve. Each determination represents the average of three indi-
vidual experiments and error bars represent the SEM. All values have had
background subtracted, which represents cell migration on membranes
coated on the bottom with BSA (1%). In control experiments, cell migra-
tion on BSA was 
 
,
 
0.01% of the total cell population.
 
Time-lapse Cell Migration and Invasion Assays
 
MCF7 or MCF7-5R cells devoid of cell surface ErbB2 receptors were
seeded onto glass coverslips coated with 3.5 
 
m
 
g/ml collagen type I and cul-
tured overnight in DME containing 10% FBS. Cells were then serum-
starved and coverslips placed into Attofluor cell chambers (Molecular
Probes, Inc.), overlaid with light mineral oil, and placed into a stage heater
(20/20 Technologies) on a Zeiss Axiovert 100TV microscope equipped
with a BioRad 1024 confocal microscope. Cells were examined for mor-
phological changes and cell movement in the presence or absence of NDF
(50 ng/ml) by collecting time-lapse images every 60 s using a Zeiss 32
 
3
 
Achrostigmat lens and LaserSharp software (BioRad).
Cell invasion experiments were performed with 8-
 
m
 
m porous invasion
chambers coated with Matrigel (Becton Dickinson) according to the man-
ufacturer’s recommendation with minor modifications. Serum-starved
cells (75,000 in 100 
 
m
 
l of FBM/0.5% BSA) were placed into the upper
chamber. The lower chamber contained 500 
 
m
 
l of FBM/0.5% BSA with or
without either 50 ng/ml EGF, NDF, BTC, or 10% FBS. Cells were al-
lowed to invade through the Matrigel membrane for 24 h. Noninvasive
cells were removed from the upper membrane and the invasive cells on
the underneath stained and counted with an inverted microscope using
the 10
 
3
 
 objective as described for the above migration experiments. 
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Determination of ERK Kinase Activity in
Migratory Cells
 
Cells were exposed to NDF (50 ng/ml) for various times and were then ex-
amined for kinase activity using either an immunocomplex kinase assay
and myelin basic protein (MBP) as a substrate, as previously described
(Klemke et al., 1997), or by immunoblotting with an antibody to the phos-
phorylated activated form of this enzyme according to the manufacturer’s
recommendation (Promega). Blots were stripped and reprobed with an
antibody to ERK2 to confirm that equal amounts of enzyme was present.
In some cases, cells were pretreated with PD98059 (50 
 
m
 
M) for 60 min be-
fore being stimulated with NDF (50 ng/ml). In other experiments, cells
were treated with NDF for 30 min before the addition of PD98059. Cells
were then examined for both kinase activity and cell migration as de-
scribed above. 
 
32
 
P incorporation into MBP was measured by excising pro-
tein bands from the gel and scintillation counting. Fold increase in ERK
kinase activity represents changes in 
 
32
 
P incorporation into MBP induced
by NDF, relative to basal kinase activity present in serum-starved non-
treated cells.
 
Transfection of MCF7 and CHO Cells, and 
Determination of CAS/Crk Complexes and ErbB 
Protein Expression in Migratory Cells
 
Transient transfection of MCF7 and MCF7-5R cells and determination of
cell migration were performed with Transwell migration chambers as pre-
viously described (Klemke et al., 1997, 1998). In brief, MCF7 cells (1.5 
 
3
 
10
 
6
 
 cells/10-cm plate) were cotransfected with lipofectamine (40 
 
m
 
l/10-cm
plate; GibcoBRL) and 7 
 
m
 
g of the expression vector containing the cDNA
encoding wild-type Crk or Crk with a mutated SH2 domain (Crk-SH2) or
wild-type CAS, or CAS without its substrate domain (CAS-SD), along
with 2 
 
m
 
g of a reporter construct encoding 
 
b
 
-galactosidase (pCMV-
 
b
 
-gal).
CAS-SD and Crk-SH2 have been described and serve as dominant nega-
tive proteins that prevent the assembly of CAS/Crk complexes in cells
(Klemke et al., 1998). In some cases, cells were transfected with mutation-
ally activated MEK (Klemke et al., 1997) as described above. Mock cells
were transfected with the appropriate amount of the empty expression
vectors. CHO cells were transfected with 3 
 
m
 
g of the appropriate vector
using 50 
 
m
 
l of effectine (Qiagen). In some cases, cells were transfected as
described above with vectors encoding human wild-type ErbB1, -2, -3, or
-4 and the reporter construct, and examined for expression of ErbB pro-
teins as previously described (Graus-Porta et al., 1996). Cells were al-
lowed to incorporate the cDNA constructs for 16 h, washed, and were
then incubated for 40 h, which provides optimal transient expression.
Cells were then prepared for migration as outlined above or analyzed for
expression of specific proteins and CAS/Crk complexes as previously de-
scribed (Klemke et al., 1997, 1998). Cells cotransfected with 
 
b
 
-gal were
developed using X-gal as a substrate according to the manufacturer’s rec-
ommendation (Promega).
Importantly, controls for transfection efficiency and cell adhesion to
ECM proteins were performed as previously described (Klemke et al.,
1998). In brief, an aliquot of cells from the migration experiments above
were allowed to attach to culture dishes coated with purified ECM pro-
teins. The dishes were washed and adherent cells transfected with the
 
b
 
-gal reporter gene were detected using X-gal as a substrate according to
the manufacturer’s recommendation (Promega). In typical transfection
experiments, we obtain 50–70% efficiency of MCF7 and 60–70% of CHO
cells as determined by counting the number of 
 
b
 
-gal positive cells relative
to the total number of cells attached per field (200
 
3
 
). It is important to
note that in an individual experiment, transfection efficiently varies
 
,
 
10%. The efficiency and adhesion control assures that changes observed
in cell migration is not simply the result of differences in transfection effi-
ciency, expression of the 
 
b
 
-gal reporter gene, or differences in the ability
of transfected cells to attach to the ECM (Klemke et al., 1997, 1998).
 
Results
 
ErbB2 Activation Is Necessary for Breast Carcinoma 
Cell Migration Induced by EGF Family Peptides
 
To determine if ErbB2 plays a direct role in cell migration
on ECM proteins, we used a novel cell model system that
employs mammary adenocarcinoma cells (MCF7, T47D,
 
and MDA-MB-435) devoid of cell surface ErbB2 recep-
tors (referred to as 5R). These cells were obtained by ret-
roviral infection with a vector that directs the expression
of an ErbB2-specific single-chain antibody genetically en-
gineered to prevent ErbB2 transit through the ER. This
results in loss of cell surface expression and functional in-
activation of the receptor (Beerli et al., 1994; Graus-Porta
et al., 1995). Importantly, since ErbB1, -3, and -4 receptor
levels, as well as basal cell proliferation rate, remain un-
changed in these cells; this allowed us to examine the spe-
cific role of ErbB2 in cell migration (Graus-Porta et al.,
1995, 1997). To investigate whether ErbB2 was necessary
for haptotaxis cell migration, cells with and without ErbB2
receptors were serum-starved and were then examined for
their ability to migrate on the ECM proteins collagen type
I and vitronectin in the presence or absence of EGF, NDF,
or BTC. MCF7-5R, T47D-5R, and MDA-MB-435-5R cells
showed a low level of basal migration on collagen and vi-
tronectin that is comparable to control cells expressing en-
dogenous levels of ErbB2 receptors, indicating that loss of
ErbB2 function did not impact the general adhesive or
basal migratory properties of these cells (data not shown).
However, exposure of wild-type cells to NDF promoted
ErbB2 tyrosine kinase activation (Fig. 1 B), resulting in a
significant (greater than tenfold) increase in cell migration
on collagen (Fig. 1 A) and vitronectin (data not shown).
As expected, NDF-induced cell migration was associated
with strong activation of ErbB3 and ErbB4, but not ErbB1
receptors (Fig. 1 B). Time-lapse microscopy revealed that
five minutes after exposure to NDF, cells showed in-
creased membrane spreading and surface ruffling (Fig. 2).
By 30 min, cells showed reduced cell–cell contacts leading
to disruption of the epithelial cell colonies and random cell
movement that was clearly visible by 60–90 min (Fig. 2). In
contrast, serum-starved control cells not exposed to NDF
did not migrate and showed little membrane ruffling. Ex-
posure of wild-type cells to EGF and BTC also induced
cell migration, although not as strongly as NDF. This
event was also associated with ErbB2 activation (Fig. 1, A
and B). As expected, exposure of cells to EGF specifically
activated ErbB1, whereas BTC promoted only ErbB1 and
ErbB4 activation. Significantly, cells devoid of functional
ErbB2 receptors failed to migrate in response to EGF,
NDF, or BTC (Fig. 1 A). These cells not only showed de-
creased cell spreading and ruffling in response to NDF,
but retained their cell–cell contacts and remained in dis-
crete epithelial colonies. Similar findings were obtained
with cells exposed to EGF and BTC (data not shown). As
expected, reexpression of ErbB2 in these cells restored
their ability to migrate in response to EGF-like peptides
(data not shown).
Interestingly, whereas the loss of ErbB2 function dra-
matically impaired the process of cell movement, it did not
abolish ErbB receptor activation in response to EGF fam-
ily peptides. In this case, EGF and BTC-induced ErbB1
activation was reduced by 
 
z
 
30–40%, whereas NDF-
induced ErbB3 and -4 activation was decreased by 
 
z
 
50%
(Fig. 1 B). Thus, the loss of cell migration in these cells did
not result from a complete loss of ErbB receptor activity,
but most likely resulted from the ability of ErbB receptor
members to transactivate ErbB2 and engage its down-
stream signals that specifically impact the migration ma- 
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chinery of cells. Importantly, the loss of cell surface ErbB2
expression did not impair the general migration machinery
of these cells since insulin induced significant migration on
collagen (Fig. 1 A) and vitronectin (data not shown),
which was comparable to wild-type cells with ErbB2 at the
plasma membrane. Cell migration induced by EGF family
peptides and insulin (data not shown) were mediated by
integrin adhesion receptors, as function blocking antibod-
ies directed to 
 
a
 
v
 
b
 
5 and 
 
b
 
1 integrins prevented T47D cell
migration on vitronectin and collagen substrates, respec-
tively (Fig. 1 C). Together, these findings indicate that cell
surface expression and activation of ErbB2 is necessary
for induction of carcinoma cell migration on the ECM in
response to EGF-related ligands.
Figure  1. Carcinoma cell migration induced by
EGF family peptides requires functional ErbB2
receptors. A, Mammary adenocarcinoma cells
lines (MCF7, T47D, and MDA-MB-435) with or
without cell surface ErbB2 receptors were serum-
starved and allowed to migrate on collagen-
coated Transwell membranes for 2 h in the pres-
ence of various concentrations of NDF, EGF,
BTC, or insulin as described in Materials and
Methods. Each point represents the mean 6
SEM of at least three independent experiments.
The background migration in cells with or with-
out ErbB2 receptors was the same and has been
subtracted. B, ErbB family receptors immuno-
precipitated from T47D cells with or without cell
surface ErbB2 (5R) after exposure to 50 ng/ml of
NDF, EGF, BTC, or buffer only (control) for 10
min. Immunoprecipitates (IP) were examined by
immunoblotting for the presence of ErbB recep-
tors, as well as changes in phosphotyrosine (PY)
as described in Materials and Methods. C, T47D
cells were allowed to migrate on collagen I or vi-
tronectin-coated Transwell membranes for 2 h in
the presence of 50 ng/ml NDF, EGF, BTC
(b-cell.) with or without 25 mg/ml of function
blocking antibodies to b1 (P4C10) or avb5
(P1F6) integrins. Data are expressed as percent
of ligand-induced migration in the absence of an-
tibodies and represents the mean 6 SEM of at
least three independent experiments. 
Spencer et al. 
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ErbB2 Activation Is Necessary for Breast Carcinoma 
Cell Invasion of the ECM 
 
Cell metastasis not only requires cell movement, but also
the ability to degrade the basement membrane and invade
the ECM. To investigate whether ErbB2 played a role in
this event, MCF7 cells were examined for their ability to
invade the basement membrane-like material Matrigel.
Exposure of cells to NDF significantly increased their abil-
ity to invade this substrate (Fig. 3 A). Cells exposed to
EGF and BTC also showed a slight increase in invasion
(Fig. 3 A). Importantly, cells devoid of cell surface ErbB2
receptors failed to invade the basement membrane in re-
sponse to NDF (Fig. 3 B), EGF, or BTC (data not shown).
However, MCF7-5R cells were capable of invasion in re-
sponse to FBS, indicating that the loss of ErbB2 function
in these cells did not impair their general invasive ability
Figure 2. Induction of carcinoma
cell migration by NDF is associated
with loss of cell–cell contacts, epi-
thelial cell scattering, and random
migration. Serum-starved MCF7
cells with or without cell surface
ErbB2 receptors (5R) were cul-
tured on collagen-coated coverslips
before being stimulated with NDF
(50 ng/ml) or buffer only (control)
and examined by time-lapse phase
microscopy for changes in cell mor-
phology and migration at the indi-
cated times. Bar, 50 mm. 
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(Fig. 3 B). Similar findings were obtained with T47D and
MDA-MB-435 cells (data not shown). Therefore, ErbB2
activation is required for induction of carcinoma cell mi-
gration, as well as invasion of the ECM in response to
EGF family peptides.
 
ERK Activation Is Necessary for ErbB2-mediated 
Carcinoma Cell Migration 
 
Exposure of cells to EGF-related peptides results in sus-
tained ERK activation (
 
.
 
2 h), while cells devoid of func-
tional ErbB2 receptors show only an early transient peak
of kinase activity that returns to basal levels by 30–40 min
(Fig. 4 A; also see Graus-Porta et al., 1995, 1997; Pinkas-
Kramarski et al., 1998). Together with our findings that
ErbB2 is required for cell migration, suggests that sus-
tained ERK activation is important for cell movement. To
examine this possibility, wild-type cells were stimulated
with NDF for 30 min and then treated with PD98059,
which prevents ERK phosphorylation and activation by
MAP kinase kinase (MEK; Dudley et al., 1995). These
cells were then examined for their ability to migrate and
for ERK activity using an in vitro kinase assay. As shown
in Fig. 4, A and B, exposure of cells to the MEK inhibitor
had little effect on NDF-induced cell migration (
 
,
 
20%)
and sustained ERK activity (
 
,
 
30%). However, exposure
of cells to the MEK inhibitor before NDF stimulation
blocked ERK activation and migration induced by this
peptide, indicating that ERK activity was necessary for the
migratory response (Fig. 4 C). Similar findings were ob-
tained with cells exposed to EGF and BTC (data not
shown). Importantly, expression of mutationally activated
MEK in cells without functional ErbB2 was sufficient to
promote cell migration and sustained ERK activation (Fig.
4 D). Therefore, the loss of cell surface expression of
ErbB2 did impact the general ability of these cells to mi-
grate in response to ERK activation. Together, these find-
ings suggest that sustained ERK activity is important for
ErbB2-mediated cell migration in response to EGF family
peptides.
 
ErbB2-dependent Migration Requires Coupling of the 
Adaptor Protein Crk to p130CAS 
 
Ligation of growth factor and integrin receptors promotes
tyrosine phosphorylation of the substrate domain of CAS
and its subsequent association with the SH2 domain of
Crk (Feller et al., 1994; Matsuda and Kurata, 1996; Ojani-
emi and Vuori, 1997; Casamassima and Rozengurt, 1998;
Klemke et al., 1998). Assembly of a CAS/Crk complex
represents a second signaling pathway distinct from ERK
that can contribute to the invasive behavior of some cells
through its ability to regulate the small GTPase, Rac (Ki-
yokawa et al., 1998; Klemke et al., 1998). To investigate
the role of ErbB2 in assembly of CAS/Crk complexes,
cells were either held in suspension or allowed to attach to
a collagen substrate in the presence or absence of NDF.
These cells were then examined for changes in CAS ty-
rosine phosphorylation and the formation of CAS/Crk
complexes. Cells in suspension showed little CAS phos-
phorylation and Crk binding, which was not altered by the
presence of NDF (Fig. 5, A and B). However, cells at-
tached to collagen in the presence of NDF showed signifi-
cantly increased CAS tyrosine phosphorylation and Crk-
binding, compared with cells attached to this substrate
without NDF (Fig. 5, A and B). The amount of detergent-
soluble CAS immunoprecipitated from cells attached to
collagen was reduced, compared with nonadherent cells
(Fig. 5 B). This may result from the ability of CAS to asso-
ciated with the Triton X-100–insoluble cytoskeleton upon
cell adhesion to the ECM (Polte and Hanks, 1997). In any
case, NDF clearly enhanced CAS phosphorylation and
formation of CAS/Crk complexes in MCF7, but not
MCF7-5R cells attached to collagen (Fig. 5, A and B). In
fact, cells devoid of ErbB2 activity showed only basal
CAS/Crk binding upon adhesion to collagen, and NDF did
not alter this response or the solubility of these proteins
(Fig. 5 B). Thus, it appears that ErbB2 can cooperate with
integrin adhesion receptors to potentiate the formation of
CAS/Crk complexes in migratory cells. To determine if as-
sembly of this adaptor protein complex was necessary for
ErbB2-dependent migration, cells were transfected with
CAS without its substrate domain (CAS-SD) or Crk with
a mutated SH2 domain (Crk-SH2). These mutant proteins
have been shown to interfere with formation of CAS/
Crk complexes and prevent downstream signals in cells
(Klemke et al., 1998). Expression of either CAS-SD or
Crk-SH2 in cells blocked migration induced by NDF (Fig.
5 C), EGF, and BTC (data not shown). Importantly, ex-
Figure 3. Functional ErbB2 receptors are required for induction
of carcinoma cell invasion of the ECM in response to EGF family
peptides. A, MCF7 cells were serum-starved and allowed to in-
vade Transwell membranes coated with the reconstituted base-
ment membrane material Matrigel for 24 h in the presence or ab-
sence of 50 ng/ml of NDF, EGF, BTC (b-cell.), or 10% FBS as
described in Materials and Methods. Each bar represents the
mean 6 SEM of at least three independent experiments. B,
MCF7 cells with and without cell surface ErbB2 receptors
(MCF7-5R) were serum-starved, then examined for their ability
to invade the reconstituted basement membrane as described
above in the presence or absence of 50 ng/ml of NDF or 10%
FBS. Each bar represents the mean 6 SEM of at least three inde-
pendent experiments. 
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pression of wild-type CAS and Crk in cells without func-
tional ErbB2 promoted cell migration (Fig. 5 D) and CAS/
Crk complexes (data not shown). Therefore, the loss of
cell surface expression of ErbB2 did not impair, nonspecif-
ically, the ability of these cells to migrate in response to
CAS/Crk coupling and its downstream signals. Together,
these findings indicate that ErbB2 activation potentiates
the assembly of a CAS/Crk signaling complex, and this
event is necessary for cell migration mediated by ErbB
family tyrosine kinases.
 
Overexpression of ErbB2 Is Sufficient to Induce 
Carcinoma Cell Migration, as well as CAS/Crk 
Coupling and ERK Activation
 
In some carcinomas, ErbB2 protein can be overexpressed
as much as 100-fold as the result of gene amplification
and/or transcriptional alterations (Hynes and Stern, 1994;
Riese and Stern, 1998). This may lead to ErbB2 tyrosine
kinase activation in the absence of ligand and induction of
cell migration and invasion. To determine whether over-
expression of ErbB2 was sufficient to induce cell migra-
tion/invasion, cells were transiently transfected with a vec-
tor encoding wild-type human ErbB2 and examined for
changes in cell migration on collagen, as well as invasion of
a reconstituted basement membrane (Matrigel). As shown
in Fig. 6 A, cells overexpressing ErbB2 showed increased
receptor activation and a three- to fourfold increase in
both migration and invasion, compared with mock cells
transfected with the empty vector. Importantly, ErbB2-
induced cell migration/invasion was associated with ERK
activation and increased assembly of CAS/Crk complexes
(Fig. 6, B and C). Treatment of these cells with the MEK
inhibitor or transfection with CAS-SD blocked ErbB2-
mediated cell migration and invasion of the basement
membrane (Fig. 6 A). These findings indicate that overex-
pression of ErbB2 was sufficient to induce cell migration
and invasion and this process required ERK activity and
CAS/Crk coupling.
To directly investigate the role of ErbB2 in cell migra-
tion independent of other ErbB members, we used CHO
cells that express a moderate level of endogenous ErbB2,
but no ErbB1, -3, or -4 (Karunagaran et al., 1996). This al-
lowed us to examine whether ErbB2 directly couples to
Figure 4. ErbB2-mediated
cell migration requires ERK
activity. A, Kinase activity of
ERK2 immunoprecipitated
from T47D cells with or with-
out cell surface ErbB2 recep-
tors (T47D-5R) after treat-
ment with 50 ng/ml NDF for
the indicated times as de-
scribed in Materials and
Methods. In some cases,
PD98059 (50 mM) was added
to T47D cells 30 min after ex-
posure to NDF to block ERK
activation by MEK. Arrow
indicates time of exposure of
cells to PD98059. B, T47D
cells pretreated for 30 min
with or without NDF (50 ng/
ml) and then allowed to
migrate on collagen-coated
Transwell membranes for 2 h
in the presence or absence of
PD98059 (50 mM). Each bar
represents the mean 6 SEM
of at least three independent
experiments. C, T47D cells
pretreated for 1 h with or
without PD98059 (50 mM)
and were then allowed to migrate on collagen-coated Transwell membranes in the presence or absence of NDF for 2 h. Each bar repre-
sents the mean 6 SEM of at least three independent experiments. An aliquot of cells treated as for the migration experiment above was
lysed in detergent then analyzed for changes in ERK activity by immunoblotting with antibodies to the phosphorylated activated form
of ERK1 and ERK2. Immunoblots were stripped and reprobed with antibodies to ERK2 to confirm equal amounts of ERK protein
were present in these lysates. D, MCF7-5R cells were transiently transfected with a b-gal reporter construct, together with either the
empty vector or the vector containing mutationally activated MEK. Cells were allowed to migrate on collagen-coated Transwell mem-
branes in the presence or absence of PD98059 for 3 h and were then stained with X-gal reagent to detect transfected cells. Transfection
efficiency, as well as cell adhesion to collagen, was monitored to assure that equal numbers of cells were transfected and loaded into mi-
gration chambers as described in Materials and Methods. Each bar represents the mean 6 SEM of at least three independent experi-
ments. An aliquot of cells treated as for the migration experiment above was lysed in detergent and analyzed for MEK expression or
changes in ERK activity by immunoblotting with antibodies to MEK or the phosphorylated activated forms of ERK1 and ERK2, re-
spectively.  
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the migration machinery of cells. As shown in Fig. 6 D,
cells overexpressing ErbB2 showed a 2.5-fold increase
in cell migration, compared with mock-transfected control
cells. This was associated with a significant increase in
ERK activity and assembly of CAS/Crk complexes (Fig. 6
D). Importantly, the MEK inhibitor or CAS-SD blocked
ErbB2-induced cell migration, indicating that ERK activ-
ity and CAS/Crk coupling were necessary for this response
(Fig. 6 D). These findings indicate that ErbB2 can directly
couple to the migration machinery of cells by activating
ERK and assembling CAS/Crk complexes.
 
Overexpression of ErbB Family Receptors Induce Cell 
Migration that Depends on ErbB2 Activation
 
Amplification of ErbB family members can lead to ty-
rosine kinase activation and development of various can-
cers (Di Fiore et al., 1987a,b; Friess et al., 1995; Gilbertson et
al., 1998; Li et al., 1999). Therefore, we investigated whether
overexpression of ErbB1, -3 and -4 receptors could also
potentiate cell migration and whether ErbB2 played a role
in this event. MCF7 and MCF7-5R cells were transfected
with either ErbB1, -3, or -4, and then examined for their
ability to migrate and for changes in ErbB receptor activa-
tion, including endogenous ErbB2. Whereas overexpres-
sion of ErbB1, -3, or -4 was sufficient to induce ErbB2
activation and MCF7 cell migration, it failed to stimulate
these events in MCF7-5R cells devoid of cell surface
ErbB2 receptors (Fig. 7, A and B). Interestingly, ErbB1, -3,
and -4 showed significant tyrosine phosphorylation that
was similar in cells with or without surface ErbB2 recep-
tors (Fig. 7 B). These findings indicate that overexpression
Figure 5. Coupling of the adaptor proteins CAS and Crk are necessary for ErbB2-mediated cell migration. A, CAS immunoprecipi-
tated from MCF7 cells with and without cell surface ErbB2 receptors (MCF7-5R) and either held in suspension (SUS) or allowed to at-
tach to collagen-coated (COLL) dishes for 15 min in the presence or absence of NDF (50 ng/ml), and then lysed in boiling 1% SDS to
completely solubilize cellular proteins. The proteins were diluted in buffer and CAS immunoprecipitated and examined for tyrosine
phosphorylation by immunoblotting with anti-phosphotyrosine antibodies as described in Materials and Methods. B, CAS immunopre-
cipitated from cells treated, as described in A, and examined for CAS tyrosine phosphorylation, as well as Crk binding by immunoblot-
ting as described in Materials and Methods. 1% Triton X-100 was used to solubilize cellular proteins in these experiments in place of
SDS. The milder lysis conditions allows for the retention CAS/Crk complexes. However, some of the CAS protein is not completely sol-
ubilized in adherent cells, most likely because it strongly associates with the detergent-insoluble cytoskeleton in cells attached to ECM
proteins (Polte and Hanks, 1997). C, MCF7 cells were transiently transfected with a b-gal reporter construct, together with either the
empty vector or the vector containing CAS with the Crk binding sites deleted (CAS-SD) or Crk with its CAS binding domain mutated
(Crk-SH2). Cells were allowed to migrate on collagen-coated Transwell membranes in the presence or absence of NDF (50 ng/ml) for
3 h and were then stained with X-gal reagent to detect transfected cells. Transfection efficiency, as well as cell adhesion to collagen, was
monitored to assure that equal numbers of cells were transfected and loaded into migration chambers as described in Materials and
Methods. Each bar represents the mean 6 SEM of at least three independent experiments. An aliquot of cells treated as for the migra-
tion experiment above was lysed in detergent then analyzed for CAS and Crk expression by immunoblotting with antibodies to CAS
and Crk. Note that the Crk-SH2 is myc-tagged and shows reduced mobility, compared with the endogenous wild-type Crk (Crk-WT)
protein as the result of the molecular tag. CAS-SD shows faster mobility, compared with endogenous CAS (CAS-WT) since its sub-
strate domain has been truncated. D, MCF7-5R cells without cell surface ErbB2 receptors were transiently transfected with a b-gal re-
porter construct, together with either the empty vector or the vector containing CAS and Crk, and then allowed to migrate as described
in C. An aliquot of cells treated as for the migration experiment above was lysed in detergent and then analyzed for CAS and Crk ex-
pression by immunoblotting with antibodies to CAS and Crk. Note that Crk and CAS are myc- and gst-tagged, respectively, and show
reduced mobility, compared with endogenous wild-type (WT) forms of these proteins. 
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of ErbB receptor tyrosine kinases in carcinoma cells is suf-
ficient for their activation in the absence of functional
ErbB2 or exogenous ligand (Fig. 7 B). However, it appears
that the basal activation of ErbB1, -3, and -4 under these
conditions does not support efficient cell migration on the
ECM in the absence of ErbB2. Furthermore, ligand-
induced migration of cells overexpressing ErbB family re-
ceptors also required ErbB2. In fact, ErbB2-deficient cells
overexpressing ErbB3 and -4 showed little capacity to mi-
grate in response to EGF ligands, compared with cells with
functional ErbB2 receptors (Fig. 7, C and D). However,
while the loss of ErbB2 activity in these cells clearly im-
paired their ability to migrate, it did not prevent receptor
activation in response to their ligands (Fig. 7 D). Interest-
ingly, ErbB2-deficient cells overexpressing ErbB1 showed
a moderate level of ligand-induced migration, although it
was not as prominent as cells with functional ErbB2 recep-
tors (Fig. 7 C). These findings suggest that cells with high
levels of ErbB1 receptor activity can engage the migration
machinery of cells in the absence of ErbB2 activation. In
contrast, overexpression and strong activation of ErbB3
and -4 in cells does not appear to fully compensate for the
loss of ErbB2 activity necessary for cell migration. The ac-
tivation of ErbB receptors in the absence of ErbB2 likely
results from their ability to form functional homodimers,
as well as heterodimers with endogenous ErbB members
present in these cells (Tzahar et al., 1996, Li et al., 1999).
Alternatively, competition for phosphatases or secretion
of EGF-like peptides could lead to ErbB receptor activity
and migration. In any case, these findings provide addi-
tional evidence that ErbB2 is critical for cell migration me-
diated by ErbB family receptors.
Figure 6. Overexpression of ErbB2 is sufficient to
induce breast carcinoma cell migration and invasion,
as well as ERK activation and CAS/Crk coupling. A,
Serum-starved MCF7 cells were transiently trans-
fected with the empty vector or the vector
(pcDNA3) containing ErbB2 along with CAS-SD
and the b-gal reporter gene. Cells were allowed to
either migrate on collagen-coated Transwell mem-
branes for 3 h or to invade the basement membrane-
like material Matrigel for 24 h and then stained with
X-gal to identify transfected migratory/invasive
cells. Transfection efficiency, as well as cell adhesion
to collagen and Matrigel, was monitored to assure
that equal numbers of cells were transfected and
loaded into the migration chamber as described in
Materials and Methods. In some cases, cells were al-
lowed to migrate or invade in the presence of
PD98059 (50 mM). Each bar represents the mean 6
SEM of at least three independent experiments. B,
Serum-starved MCF7 cells transiently transfected
with the empty vector or the vector (pcDNA3) con-
taining ErbB2 were lysed and examined for ErbB2
expression and tyrosine phosphorylation, as well as
ERK activation by immunoblotting as described in
Materials and Methods. C, CAS immunoprecipi-
tated from protein lysates of cells transfected as de-
scribed in B were either held in suspension (SUS) or
allowed to attach to collagen-coated (COLL) dishes
for 15 min. The immunoprecipitates were examined
for tyrosine phosphorylation of CAS, as well as Crk,
binding by immunoblotting as described in Materi-
als and Methods. D, Serum-starved CHO cells were
transiently transfected with the empty vector or the
vector (pcDNA3) containing ErbB2 or CAS-SD
along with the b-gal reporter gene. Cells were al-
lowed to migrate on fibronectin-coated Transwell
membranes for 3 h in the presence or absence of
PD98059 (50 mM) as described in A. An aliquot of
cells treated as for the migration experiments above
was lysed and examined for ErbB2 expression and
tyrosine phosphorylation, as well as ERK activation,
by immunoblotting as described in Materials and
Methods. CAS was also immunoprecipitated from
protein lysates of cells transfected with ErbB2 or the
empty control vector after attachment to fibronec-
tin-coated dishes for 15 min and examined for Crk
binding by immunoblotting with Crk antibodies.  
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Discussion
 
Evidence that ErbB2 Activation Is Critical for 
Induction of Cell Migration and Invasion of the ECM
 
Cell migration is an underlying component of develop-
ment, angiogenesis, wound healing, and tumor cell me-
tastasis. While ErbB family receptors and their ligands are
involved in the regulation of these biological processes, it
has been difficult to link specific ErbB receptor activation
events to a given biological response since most cells ex-
press multiple ErbB members (Hynes and Stern, 1994;
Riese and Stern, 1998). Even more complexity is intro-
duced by the fact that these receptors undergo multiple
heterodimerization and transactivation events upon ligand
binding or overexpression (Tzahar et al., 1996). It appears
then that the potential of an ErbB receptor to regulate a
given biological process is dependent on the type of ligand
present, as well as the complement of ErbB receptors ex-
pressed by a given cell type. The ability for receptor cross-
talk is important as it diversifies downstream signals and
the potential to control numerous biological processes. In
this study, we used carcinoma cells depleted of cell surface
ErbB2 receptors to study its specific role in cell invasion of
the ECM. We provide several lines of evidence that ErbB2
serves as a central signaling component required for cell
migration and invasion induced by EGF family receptors.
First, breast carcinoma cell lines exposed to several EGF-
related peptides were induced to migrate and invade the
ECM, whereas cells devoid of functional ErbB2 receptors
did not. Second, only cells expressing functional ErbB2 re-
ceptors potentiated ERK activity and CAS/Crk coupling,
two signaling pathways associated with induction of cell
movement (Klemke et al., 1997, 1998). Third, overexpres-
sion of ErbB2 in cells was sufficient to induce cell invasion
Figure 7. ErbB2 activation is necessary for cell migration induced by overexpression of ErbB family receptors. A, Serum-starved MCF7
cells with or without cell surface ErbB2 receptors (MCF7-5R) were transiently transfected with either the empty vector (Mock) or the
vector (pcDNA3) containing either ErbB1, ErbB3, or ErbB4 along with the b-gal reporter gene. Cells were allowed to migrate on col-
lagen-coated Transwell membranes for 3 h and then stained with X-gal to identify transfected migratory cells. Transfection efficiency,
as well as cell adhesion to collagen, was monitored to assure that equal numbers of transfected cells were loaded into the migration
chamber as described in Materials and Methods. B, Immunoprecipitation of ErbB1, -3, or -4 from cells treated as for the migration ex-
periments above and examined for expression, as well as changes in tyrosine phosphorylation by immunoblotting as described in Mate-
rials and Methods. Note that endogenous ErbB2 was also immunoprecipitated from these cells and examined for changes in tyrosine
phosphorylation. In these experiments, ErbB1, -3, and -4 were overexpressed above endogenous proteins by z56-, 30-, and 48-fold, re-
spectively, as determined by immunoblotting with ErbB antibodies and ECL. MCF7 cells express moderate levels of endogenous
ErbB3, -4, and a low level of ErbB1 receptors, which are not visible at the short exposure time (5 s) used to visualize the overexpressed
proteins in these experiments. C, Cells transfected as described in A were allowed to migrate for 3 h in the presence of various concen-
trations of EGF, NDF, or BTC as described above. The basal migration of these cells in the absence of EGF-like peptides has been sub-
tracted as background. D, Immunoprecipitation of ErbB1, -3, or -4 from cells treated as for the migration experiments in C. ErbB recep-
tor (ErbBR) expression, as well as changes in tyrosine phosphorylation, were determined in cells exposed to the indicated ligand (50 ng/
ml for 10 min) by immunoblotting as described in Materials and Methods. Note that endogenous ErbB2 was also immunoprecipitated
from these cells and examined for changes in tyrosine phosphorylation. Each bar or data point represents the mean 6 SEM of at least
three independent experiments. 
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and facilitate ERK activity and CAS/Crk coupling. Fi-
nally, overexpression of ErbB1, -3, and -4 induced cell mi-
gration that was mediated by ErbB2 activation. Interest-
ingly, it is known that ErbB1 facilitates cell migration
through critical tyrosine residues in its cytoplasmic tail
(Chen et al., 1994). Recent evidence indicates that this re-
gion of ErbB1 may be dispensable for its signaling proper-
ties since it can associate with and signal through the
ErbB2 receptor (Wong et al., 1999). Furthermore, mice
deficient in ErbB2 display almost identical developmental
abnormalities as NDF, and ErbB4 deficient animals (Gass-
mann et al., 1995; Lee et al., 1995; Riethmacher et al.,
1997). Together, these findings suggest that ErbB2 serves
as an integral partner of the ErbB receptor signaling net-
work and the physiological processes mediated by this
family of receptor tyrosine kinases.
 
Mechanisms of ErbB2-dependent Cell Invasion
 
One of the most significant effects associated with ErbB2
activation is enhanced and prolonged signaling events, in-
cluding sustained activation of ERK (Graus-Porta et al.,
1995; Karunagaran et al., 1996; Pinkas-Kramarski et al.,
1998). We show here that an important consequence of
this event is to facilitate cell invasion. ERK can phosphor-
ylate myosin light chain kinase, leading to increased myo-
sin phosphorylation and motor activity during cell migra-
tion (Klemke et al., 1997). This may be due to the ability of
ErbB2 to enhance binding affinities for EGF peptides,
leading to an increase in the half-life of receptor-ligand
complexes and downstream signals that impact ERK ac-
tivity and myosin function (Karunagaran et al., 1996).
However, ErbB2 alone can stimulate sustained ERK acti-
vation independent of other ErbB members, indicating
that it directly couples to this signaling pathway (Fig. 4 D;
and Ben-Levy et al., 1994). The ability of ErbB2 to facili-
tate sustained ERK signaling may be responsible for the
highly proliferative, as well as malignant, nature of tumors
that arise from aberrant ErbB2 receptor activation. In
breast cancer patients, ERK activity is sustained five- to
tenfold over benign conditions and is localized to meta-
static cells within the lymph nodes (Sivaraman et al., 1997).
The inability of ErbB2-deficient cells to move in re-
sponse to EGF family peptides does not appear to result
from a complete loss of ErbB receptor activity. Therefore,
it seems that the role of ErbB2 in migration is to diversify
receptor transphosphorylation events and to provide
unique downstream effector molecules that specifically
link ErbB receptors to the migration and invasion machin-
ery of cells. Our findings, that overexpression of ErbB2 in
cells devoid of other ErbB members is sufficient to induce
cell migration, support this notion. Furthermore, ErbB2-
deficient cells overexpressing ErbB1, -3, or -4 show strong
receptor activation, but impaired migration in response to
EGF-like peptides. Recent evidence also indicates that
overexpression of ErbB2 in NIH 3T3 fibroblast cells pro-
motes cell migration (Verbeek et al., 1998). However, it is
not clear whether ErbB1 present in these cells contributes
to the migration response.
ErbB receptor heterodimerization with ErbB2 was re-
cently shown to cause differential patterns of tyrosine
phosphorylation of ErbB2 (Olayioye et al., 1998). These
phosphotyrosine residues may serve as SH2 docking sites
for unique effectors, such as CHK (CSK-homologous ki-
nase), Grb2, c-src, Shc, and the p85 subunit of PI3 kinase
(Alroy and Yarden, 1997). CHK is of particular interest
since this kinase specifically binds to the activated ErbB2
receptor and regulates c-src activation (Zrihan-Licht et al.,
1997). c-Src is known to facilitate CAS/Crk coupling, as
well as ERK activation in cells (Vuori et al., 1996). Fur-
thermore, mammary carcinomas that result from ErbB2
amplification show significantly elevated c-src activity (Ot-
tenhoff-Kalff et al., 1992; Luttrell et al., 1994; Muth-
uswamy et al., 1994). It seems possible, then, that c-src
could play a pivotal role in coupling ErbB2 to the migra-
tion machinery of cells by mediating ERK activation and
CAS/Crk coupling.
ErbB2 may also serve to target ErbB receptor/signaling
complexes to a specific site(s) in cells. Both CAS/Crk and
ErbB2 localize to membrane ruffles of migratory cells (De
Potter and Quatacker, 1993; Klemke et al., 1998; Wang et al.,
1999). Assembly of a CAS/Crk complex is associated with
Rac activation and formation of membrane ruffles (Ki-
yokawa et al., 1998; Klemke et al., 1998). This, and the fact
that ErbB2 activation facilitates down-regulation of cell–
cell contacts resulting in an epithelial-mesenchymal transi-
tion, may explain the increased metastatic properties asso-
ciated with carcinoma cells with amplified ErbB2. Rac
activation and loss of cell–cell contacts enhances cell inva-
sion and metastasis of breast carcinoma cells (Keely et al.,
1997). Interestingly, ErbB2 can associate with integrin ad-
hesion receptors (Falcioni et al., 1997), and integrin liga-
tion induces ErbB1 activation (Moro et al., 1998). There-
fore, ErbB2 may play a role in regulation of integrin
adhesiveness and/or signaling during cell migration on the
ECM. Our findings, that ErbB2 activation can potentiate
CAS/Crk coupling during cell adhesion to the ECM, sug-
gests that integrin and ErbB2 receptors cooperate to regu-
late cell migration.
 
Biological Importance of ErbB2-mediated
Cell Migration/Invasion
 
Our findings that ErbB2 is necessary for the process of cell
migration has implications for a number of biological, as
well as certain pathological, processes associated with
ErbB family receptors and their ligands. For example,
ErbB receptors have been implicated in the development
of a number of human cancers (Slamon et al., 1989; Dou-
gall et al., 1994; Hynes and Stern, 1994; Gilbertson et al.,
1998). In fact, many of these tumors were found to overex-
press one or more of the ErbB receptors that were associ-
ated with increased occurrence of visceral metastasis and
micrometastatic bone marrow disease (Pantel et al., 1993).
Our findings raise the possibility that the increased inva-
sive potential and poor prognosis associated with these
carcinomas may be directly related to their ability to cou-
ple to and transactivate ErbB2 and the migration machin-
ery. Since ErbB2 is the preferred partner recruited by all
activated ErbB receptors, it seems reasonable that an
ErbB2 homo- or heterodimer is responsible for these mi-
gration/metastasis events (Graus-Porta et al., 1997). This
could occur as a result of ErbB receptor amplification,
which is known to facilitate increased molecular interac- 
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tions among receptor members, leading to their dimeriza-
tion and activation in the absence of ligand (Stern et al.,
1988). Our findings, that overexpression of ErbB recep-
tors in carcinoma cells is sufficient to promote ErbB2 acti-
vation in the absence of exogenous ligand, support this no-
tion (Fig. 7). ErbB2 containing heterodimers would also
be expected to occur in carcinoma cells exposed to EGF
family peptides that are common in the extracellular envi-
ronment of many tissues, including mammary glands
(Yang et al., 1995; Jones et al., 1996). Alternatively, some
carcinoma cells are known to secrete EGF-related pep-
tides, including NDF and TGF-
 
a
 
, suggesting that ErbB2
activation may occur by an autocrine mechanism (Bacus
et al., 1993). Thus, the poor prognosis associated with can-
cers that arise from altered ErbB receptor members could
be due, in part, to enhanced migration/invasion as the re-
sult of ErbB2 activation via an autocrine and/or paracrine
mechanism.
Mice lacking ErbB2 die in utero due to defects in neural
and cardiac development (Lee et al., 1995). The neural de-
fects seen in these animals may result from a deficiency in
neural crest cell proliferation and/or migration (Lee et al.,
1995; Britsch et al., 1998). Remarkably, mice deficient in
ErbB4 or NDF show an almost identical phenotype to that
of ErbB2 deficient animals (Gassmann et al., 1995; Meyer
and Birchmeier, 1995). These findings are consistent with
the idea that ErbB2 activation is a central event in the sig-
nal transduction mechanism of ErbB family receptors and
their biological responses, including cell migration. ErbB
receptors and EGF family peptides are also expressed
during normal development of the mammary gland (Yang
et al., 1995; Jones et al., 1996). NDF has been shown to
promote in vitro cell migration and morphogenic changes
that resemble the development of tubular and alveolar
structures present in the mammary gland (Chausovsky
et al., 1998; Niemann et al., 1998). Moreover, these events
are associated with both ErbB2 and ErbB3 activation, sug-
gesting that an ErbB2/3 heterodimer is important for this
process.
There may also be instances in which cells lacking
ErbB2 can migrate in response to EGF family peptides
(Rio et al., 1997). Fibroblast cells overexpressing ErbB1 or
-4 alone can be stimulated to migrate with EGF and HB-
EGF, respectively (Elenius et al., 1997). We found that ac-
tivation of ErbB1 in carcinoma cells overexpressing this
receptor was sufficient to induce a moderate level of mi-
gration in the absence of ErbB2 (Fig. 7). Thus, it is possi-
ble that some cells compensate for the lack of ErbB2 sig-
nals through receptor transactivation events associated
with receptor amplification and dimerization. This, in turn,
could upregulate and/or provide unique signals for cell mi-
gration.
In summary, our findings demonstrate that ErbB2 plays
a central role in promoting breast carcinoma cell invasion
of the ECM. ErbB2 serves as a fundamental signaling
component that links ErbB family receptor tyrosine ki-
nases to the migration/invasion machinery of carcinoma
cells by facilitating ERK activation and CAS/Crk cou-
pling. These findings contribute to the understanding of
how ErbB family receptors and their ligands regulate
signal transduction events associated with development,
wound repair, angiogenesis, and tumor cell dissemination.
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